Herbert Irving Comprehensive Cancer Center
There are eight research programs at HICCC divided into three divisions. The basic research division includes programs in cancer regulatory networks and cancer genetics and epigenetics. Programs in the disease-specific division focus on breast cancer, hematological cancer, prostate cancer, and neuro-oncology. The population science division includes cancer epidemiology and prevention, control, and disparities. The center is currently receiving over $33 million in funding from the National Institutes of Health. Patients are treated at NewYork-Presbyterian Hospital/Columbia. HICCC physicians treat more than 3,500 patients annually. There are over 200 clinical trials available to patients. First opened in 1911 as the Institute for Cancer Research, it soon moved to its current location at Columbia-Presbyterian Medical Center. HICC received its NCI designation in 1972, being promoted to comprehensive status in 1979. After a 1998 merger, the campus name was changed to Columbia University Medical Center, remaining an academic medical center and becoming the largest campus of NewYork-Presbyterian Hospital. In 2017, Herbert and Florence Irving gave a transformative $700 million gift to Columbia University and NewYork-Presbyterian to dramatically advance research and clinical programs for the treatment of cancer. In recognition of a lifetime of philanthropy, the Hospital and the University jointly renamed the campus to its current name, Columbia University Irving Medical Center. HICCC was previously led by Stephen G. Emerson, and the current interim director is Cory Abate-Shen, with Gary Schwartz as the deputy director.
History
Herbert Irving Comprehensive Cancer Center (HICCC) is a National Cancer Institute NCI-designated Cancer Center, founded in 1911 and located at NewYork-Presbyterian / Columbia University Irving Medical Center (NYP/CUIMC).